Table 4. Breast cancer-specific mortality obtained using the Kaplan–Meier (KM) approach by not adjusting for competing risk events, and estimated by adjusting for competing risk events (CR).
|
Mortality due to breast cancer |
||||
|---|---|---|---|---|
| Overall (%) | BRCA mutation (%) | No mutation (%) | ||
| N (BCSS) | 305 (43) | 28 (8) | 276 (35) | |
| % Censored | KM | 86 | 71 | 87 |
| CR | 77 | 64 | 79 | |
| 1 year | KM | 0.3 | 3.6 | 0.0 |
| CR | 0.3 | 3.6 | 0.0 | |
| 5 year | KM | 4.4 | 10.9 | 3.7 |
| CR | 4.3 | 10.7 | 3.7 | |
| 10 year | KM | 14.2 | 28.4 | 12.8 |
| CR | 13.6 | 27.0 | 12.3 | |
| 15 year | KM | 18.6 | 37.3 | 16.7 |
| CR | 17.6 | 35.2 | 15.9 | |
Column 3 (‘Overall’) shows the cumulative incidence for all the 305 breast cancer patients. Columns 4 and 5 show the cumulative incidence estimates for patients with and without a BRCA mutation. The sample size is denoted N. The number of breast cancer-specific deaths is denoted BCSS and is given in parentheses in the second row. One patient without a BRCA mutation had missing death status and hence was excluded from the analysis.